Rybkin, Igor I.
Henry Ford Health · Henry Ford Hospital
7 papers on CoChatORCID 0000-0002-8434-1093
Most cited papers
- Verified
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery
Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways
Cited by 1,304
- Verified
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine
Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways
Cited by 1,247
- Verified
Transcriptional coactivator PGC-1α controls the energy state and contractile function of cardiac muscle
Arany, Z., He, H., Lin, J., Hoyer, K., Handschin, C., Toka, O., Ahmad, F., Matsui, T., Chin, S., Wu, P.-H., et al. (2005) · Cell Metabolism
Adipose Tissue and MetabolismMitochondrial Function and Pathology
Cited by 694
- Verified
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1)
Ou, S.-H. I., Jänne, P. A., Leal, T. A., Rybkin, I. I., Sabari, J. K., Barve, M. A., Bazhenova, L., Johnson, M. L., Velastegui, K. L., Cilliers, C., et al. (2022) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 322
- Verified
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
Jänne, P. A., Rybkin, I. I., Spira, A. I., Riely, G. J., Papadopoulos, K. P., Sabari, J. K., Johnson, M. L., Heist, R. S., Bazhenova, L., Barve, M., et al. (2020) · European Journal of Cancer
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 140
- Verified
99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation
Riely, G. J., Ou, S.-H. I., Rybkin, I., Spira, A., Papadopoulos, K., Sabari, J. K., Johnson, M., Heist, R. S., Bazhenova, L., Barve, M., et al. (2021) · Journal of Thoracic Oncology
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 77
- Verified
KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRAS G12C mutation
Johnson, M. L., Ou, S. H. I., Barve, M., Rybkin, I. I., Papadopoulos, K. P., Leal, T. A., Velastegui, K., Christensen, J. G., Kheoh, T., Chao, R. C., et al. (2020) · European Journal of Cancer
Colorectal Cancer Treatments and StudiesProtein Kinase Regulation and GTPase Signaling
Cited by 77
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free